The role of mast cells in Autism Spectrum Disorder.

This review looks at special immune cells called mast cells and how they might be involved in autism. These cells, which normally help with allergic reactions, may contribute to autism by causing brain inflammation, affecting the immune system, and disrupting gut health. The researchers suggest that targeting these cells with medications could be a new way to help treat autism symptoms.

This comprehensive review examines the role of mast cells (immune cells traditionally linked to allergic reactions) in Autism Spectrum Disorder pathophysiology. The authors propose that increased mast cell activity may contribute to ASD development through three key mechanisms: neuroinflammation via mediators like histamine and cytokines, autoimmune processes affecting both patients and mothers, and gut-brain axis disruptions leading to gastrointestinal comorbidities. The review suggests mast cells interact with immune and neuronal cells, potentially influencing ASD symptoms through altered neuroinflammatory pathways, lymphocyte modulation, and gut permeability changes. The authors conclude that targeting mast cell activity through pharmacological interventions represents a promising therapeutic avenue for ASD treatment.

Targeting mast cell activity through pharmacological agents offers promising therapeutic avenues for ASD. The gut-brain axis involvement suggests gastrointestinal interventions may benefit autism symptoms. Immune-based treatments represent potential novel approaches, though clinical validation is needed.

As a narrative review, findings represent synthesis of existing literature rather than new empirical data. No sample size reported. The mechanisms proposed require further validation through controlled studies. Clinical translation of mast cell-targeted therapies needs empirical testing.

Autism Spectrum Disorder (ASD) comprises a group of neurodevelopmental disorders characterized by alterations in communication, repetitive behaviors and impaired socialization. The precise etiology and pathogenesis remain unclear, and there is currently no effective treatment for this condition. Emerging research highlights the role of immune dysregulation in ASD pathophysiology. Mast cells (MCs) are immune cells traditionally associated with allergic diseases but also play a crucial role in other inflammatory and immune processes.

Increased MC activity may be linked to the development of ASD in certain patients. This review explores the potential mechanisms involving MCs in ASD, including neuroinflammation, autoimmunity, and disruptions in the gut-brain axis. Evidence suggests that MC mediators such as histamine, serotonin, and cytokines influence neuroinflammatory pathways that are altered in ASD, and MCs can interact with other immune and neuronal cells contributing to ASD symptoms. Autoimmunity is frequently present in both ASD patients and their mothers, and MCs could originate these processes by modulation of lymphocyte populations or secretion of self-antigens.

Finally, MC involvement in gut permeability and microbiota dysbiosis underscores their role in gastrointestinal comorbidities frequent in ASD. Targeting MC activity through pharmacological agents offers promising therapeutic avenues. This comprehensive review sheds light on immune-mediated processes underlying ASD and discusses potential future strategies for intervention.